What changed for Psoriatic Arthritis
A plain English summary of what recently moved in the public data Voxsanity tracks for Psoriatic Arthritis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 5 to 6 (+1)
- Trials recruiting worldwide 82 to 77 (-5)
- Late-stage (Phase 3) trials 13 to 12 (-1)
- Trials on record 546 to 476 (-70)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Psoriatic Arthritis in July 2026. Voxsanity tracks 14 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 96 trials tracked for Psoriatic Arthritis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05071664 · results posted 23 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05071664) enrolled 91 people with psoriatic arthritis — a condition involving joint inflammation and skin psoriasis. Participants were split into two groups: 59 people received a combination of two medicines (guselkumab plus golimumab), and 32 people received guselkumab plus a placebo (an inactive substitute). The trial's main goal was to measure how many people in each group reached what researchers called "Minimal Disease Activity" (MDA) at 24 weeks — a benchmark meaning a person's disease had reached a low enough level...
-
NCT03531073 · results posted 22 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03531073) enrolled 446 people with psoriatic arthritis — a condition involving joint inflammation alongside psoriasis — all placed in a single "Standard Care Cohort," meaning they received their usual medical care. Of those who started, 300 completed the study and 146 did not finish. The trial was measuring two things: how active participants' psoriatic arthritis was, and how much the condition was affecting their day-to-day life. The reported data shows that for the primary measure — the Psoriatic Arthritis Disease Activ...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04882098 · results posted 4 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,054 participants in total across three groups. The first group (388 people) received guselkumab injections every 8 weeks, the second group (280 people) received guselkumab every 4 weeks, and the third group (386 people) started on a placebo (an inactive treatment) before later switching to guselkumab. The trial was looking at how these treatments affected psoriatic arthritis — a condition involving joint pain and swelling linked to psoriasis. The main thing being measured was whether participants' joint swelling, te...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04108468 · results posted 2 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04108468) enrolled 84 adults with psoriatic arthritis — 41 in a group receiving methotrexate alone, and 43 in a group receiving both golimumab and methotrexate. The trial was measuring disease activity using two scoring tools across multiple time points over about a year. Of those who started, 38 in the methotrexate group and 39 in the combination group completed the study. The primary measurement used was the Psoriatic Arthritis Disease Activity Score (PASDAS) — a scale from 0 to 10 where a higher number means more disea...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04908202 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04908202) looked at a medicine called deucravacitinib (taken as a 6 mg daily tablet) compared to a placebo (a dummy tablet with no active ingredient) in people with psoriatic arthritis. A total of 670 people entered the initial phase — 336 in the deucravacitinib group and 334 in the placebo group. The trial was structured in two stages: a placebo-controlled period (where neither participants nor researchers knew who was getting which tablet) and a later active-treatment period where everyone received the real medicine. The...
-
NCT05855967 · results posted 22 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05855967) enrolled 250 participants in total — 150 people who had the skin condition psoriasis (PsO) without active joint involvement, and 100 people who had psoriasis alongside active psoriatic arthritis (PsA). All 250 received at least one dose of the study drug, ixekizumab, and the large majority completed the trial (141 and 94 participants respectively). The trial was measuring a range of things, including unwanted medical events that occurred during treatment, how much participants' skin improved, how doctors rated ov...
-
NCT03885089 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial involved 10 people who received an infliximab biosimilar (a medicine very similar to an already-approved treatment, made by Pfizer) given by intravenous drip. The trial was conducted in a single group — there was no comparison group. Eight of the 10 participants completed the study, and two did not finish. The trial was measuring two main things: any unwanted reactions that were linked to the medicine, and changes in the severity of participants' psoriasis (a skin condition) using standard scoring tools. The reported data sho...
-
NCT04527380 · results posted 5 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04527380) involved 101 children and young people with Juvenile Idiopathic Arthritis (JIA) — a form of arthritis that affects children. Eighty-one participants received a medicine called ixekizumab, and 20 received a medicine called adalimumab, during what was called the "open-label treatment" (OLT) period, meaning everyone knew which medicine they were taking. The trial was measuring how many participants showed meaningful improvements in their arthritis, using a standard scoring system that looks at things like swollen jo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03769168 · results posted 23 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03769168) involved 55 young people with Juvenile Idiopathic Arthritis (a form of arthritis that affects children and teenagers). Nineteen participants received a lower dose of a medicine called secukinumab (75 mg) and 36 received a higher dose (150 mg). Some participants later had their dose increased during the study. The trial was measuring how many participants showed improvement across six areas, including joint activity, physical function, and inflammation levels — using a scoring system called JIA ACR, which tracks w...
-
NCT04908189 · results posted 13 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04908189) enrolled 729 people across three groups: 312 received a medicine called deucravacitinib, 312 received a placebo (a dummy treatment with no active ingredient), and 105 received another medicine called apremilast. The trial was primarily measuring how many participants in the deucravacitinib and placebo groups showed at least a 20% improvement in joint tenderness, joint swelling, and several other disease-related measures by week 16 — a standard benchmark in arthritis research known as "ACR 20." Several secondary m...
-
NCT01550003 · results posted 23 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 193 children and young people in total, split into three groups based on body weight: 18 participants weighing 10 to under 20 kg, 63 weighing 20 to under 40 kg, and 112 weighing 40 kg or more. The trial was measuring how much of the study drug, certolizumab pegol (CZP), was present in participants' blood at certain time points, whether the body produced antibodies (proteins that can react against the drug) in response to it, and how many participants experienced serious unwanted medical events or had to stop taking th...
-
NCT03895203 · results posted 23 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03895203) enrolled 852 adults with psoriatic arthritis across three groups during the first 16-week phase: 281 received a placebo (inactive treatment), 431 received bimekizumab (BKZ) at 160 mg every four weeks, and 140 received adalimumab (ADA) at 40 mg every two weeks. The trial was measuring how well these treatments reduced joint and skin symptoms of psoriatic arthritis over time, using a range of standardised scoring tools to track things like joint tenderness and swelling, skin coverage, physical function, and overall...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03896581 · results posted 16 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03896581) enrolled 400 people — 133 received a placebo (an inactive dummy treatment) and 267 received a medicine called bimekizumab 160mg. The vast majority completed the trial: 125 in the placebo group and 263 in the bimekizumab group. The trial was primarily measuring what proportion of participants achieved an "ACR50 response" — meaning their joint tenderness, joint swelling, and several other arthritis-related measures all improved by at least 50% from where they started. It also looked at a range of secondary measures...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05758402 · results posted 10 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 368 people with moderate to severe psoriasis (a skin condition) across two groups: 181 participants in the "EARP Group," where a short questionnaire called the EARP was used to screen for psoriatic arthritis (a type of joint inflammation that can occur alongside psoriasis), and 187 participants in the "Routine Practice Group," where doctors used their own clinical judgement to decide who might have the condition. All participants completed the study with no drop-outs reported. The trial's main goal was to compare how...
-
NCT05171270 · results posted 25 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 503 adults with psoriatic arthritis, and all 503 completed the study. The trial was looking at how treatment decisions were made during medical consultations — specifically, how often doctors changed a patient's treatment (either stepping it up or scaling it back), and how patients felt about their condition and their interactions with their doctor. It also looked at whether a patient-reported questionnaire called the PsAID-12 — which asks people to rate how much their psoriatic arthritis affects their daily life on a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04209205 · results posted 26 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04209205) enrolled 381 adults with psoriatic arthritis — a condition involving joint inflammation alongside the skin condition psoriasis. Around 191 people received the active drug, AIN457 (also known as secukinumab), given by intravenous drip at a starting dose of 6 mg/kg followed by 3 mg/kg, while 190 people received a placebo (an inactive dummy infusion). The trial's main goal was to measure how many participants showed a meaningful reduction in joint tenderness and swelling — plus improvements in pain, physical functio...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03747939 · results posted 5 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03747939) enrolled 308 participants in its first phase — 105 received a placebo (a dummy treatment with no active ingredient) and 203 received apremilast 30 mg. The trial was measuring how many people with psoriatic arthritis reached what researchers called "minimal disease activity" — a specific threshold where joint swelling, joint tenderness, skin involvement, pain, physical function, and tendon-area tenderness all fell within very low ranges at the same time. This was the main question the trial set out to answer at th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04109976 · results posted 30 November 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 214 participants in total — 107 people in each of two groups. One group used a standard safety syringe (called BKZ-SS) to inject themselves with a medicine called bimekizumab, and the other group used an auto-injector device (called BKZ-AI) to do the same. The trial was measuring whether participants could successfully give themselves the full dose using these devices, without experiencing any device-related problems serious enough to stop them continuing. Nearly all participants finished the trial — 106 out of 107 co...
-
NCT03926195 · results posted 1 August 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 109 male participants — 54 taking filgotinib (a medication being studied) and 55 taking a placebo (an inactive dummy treatment). The trial was designed to measure whether filgotinib affected sperm, specifically looking at sperm concentration (how many sperm are in a sample), sperm movement, and total sperm count. The main question the trial asked was whether participants experienced a drop of 50% or more in sperm concentration after 13 weeks of treatment. The trial also included a longer extension phase running up to...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02925338 · results posted 25 January 2023
According to the results reported on ClinicalTrials.gov, this observational study followed 1,426 people across five condition groups over two years. The groups were: Crohn's Disease (547 people), Ulcerative Colitis (230), Rheumatoid Arthritis (142), Ankylosing Spondylitis (411), and Psoriatic Arthritis (96). Most participants were adults, with a small number of children included in the Crohn's Disease and Ulcerative Colitis groups only. The study was tracking how people went while receiving Inflectra (a medicine given by infusion), looking at things like how long they stayed on the treatment w...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01421069 · results posted 14 November 2022
According to the results reported on ClinicalTrials.gov, this trial involved 127 participants in the initial (parent) study phase, all of whom received the medication etanercept. Of those, 119 completed that phase. The study then continued into an extension phase, where 109 participants went on to take part, with 84 ultimately completing the extension. The trial was designed to track and record certain medical events — specifically cancers, serious medical events, and infections — that occurred in participants over the course of both the parent and extension study periods. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03773978 · results posted 7 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03773978) looked at baricitinib, a tablet medicine, in children and young people with juvenile idiopathic arthritis (JIA) — a form of arthritis that affects children. The trial had two main stages. In the first stage, 220 participants all received baricitinib, to check how their bodies handled the medicine and to allow their disease to settle. In the second, "double-blind withdrawal" stage, 82 participants continued on baricitinib and 81 were switched to a placebo (a dummy tablet with no active medicine), without anyone kn...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03031782 · results posted 15 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03031782) studied a medicine called AIN457 (also known as secukinumab) in children and young people with two forms of juvenile idiopathic arthritis — a type of long-term joint condition in children. The trial ran in up to three treatment periods. In the first period, 86 participants started and 83 finished. In the second period, 75 participants were split between the active medicine and a dummy treatment (placebo), and in the third period, 11 participants received the active medicine. The trial measured things like disease...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04115748 · results posted 16 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04115748) enrolled 67 people across four groups during the main 16-week study: 19 received filgotinib 200 mg, 19 received filgotinib 100 mg, 9 received adalimumab 40 mg, and 20 received a placebo (a dummy treatment with no active ingredient). A smaller long-term extension then followed participants who completed the main study through to week 50, though none completed that extension phase. The trial was measuring various aspects of psoriatic arthritis disease activity, including joint tenderness and swelling, skin involvem...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03410992 · results posted 4 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03410992) enrolled 435 people with moderate to severe plaque psoriasis — 86 received a placebo (a dummy treatment with no active ingredient) and 349 received bimekizumab 320 mg given every four weeks. The trial was primarily measuring how many participants showed a large improvement in their psoriasis by week 16, using two standard skin-scoring tools: one called PASI (which rates the redness, thickness, and scaling of psoriasis patches across the body) and another called IGA (where a doctor rates overall severity on a scal...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03671148 · results posted 2 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03671148) enrolled 444 people in total — 220 in the placebo group and 224 in the risankizumab group — all of whom had psoriatic arthritis (a condition involving joint inflammation alongside the skin condition psoriasis). The trial's main goal was to measure how many participants showed a meaningful improvement in their joint symptoms after 24 weeks, using a standard checklist called the ACR20, which looks at tender joints, swollen joints, pain, physical function, and inflammation markers. The reported data shows that at t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03675308 · results posted 24 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03675308) enrolled 964 people — 481 in the placebo group and 483 in the risankizumab group. The vast majority completed the study (467 and 473 respectively). The trial was measuring outcomes in people with psoriatic arthritis, a condition involving joint inflammation and skin psoriasis. The main thing researchers were tracking at 24 weeks was whether participants reached a standardised level of joint improvement, known as an "ACR20 response" — meaning at least a 20% improvement in tender joints, swollen joints, and several...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03370133 · results posted 3 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03370133) involved people with psoriasis and compared three options: a placebo (inactive treatment), bimekizumab (320 mg every four weeks), and ustekinumab. A total of 567 people entered the first phase of the trial — 83 received placebo, 321 received bimekizumab, and 163 received ustekinumab. The trial was primarily measuring two things at the 16-week mark: how many participants achieved at least a 90% reduction in their skin disease score (using a detailed scoring system called PASI, which rates the redness, thickness, s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03104374 · results posted 25 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03104374) enrolled 642 adults across four groups to study the drug upadacitinib in people with psoriatic arthritis. Two groups received upadacitinib from the start — either a 15 mg or 30 mg daily dose — while two groups started on a placebo (an inactive dummy treatment) before later switching to upadacitinib. The trial ran in two periods, and the main thing it was measuring was how many participants showed at least a 20% improvement in joint tenderness, joint swelling, and several other disease markers by week 12 — a stand...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03104400 · results posted 25 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03104400) looked at people with psoriatic arthritis — a condition involving joint inflammation and skin symptoms. In the first phase of the trial (up to about one year), 1,705 participants were enrolled across five groups: one receiving a placebo (dummy treatment), one receiving adalimumab (an existing medicine), and three receiving different doses or schedules of upadacitinib (the medicine being studied). A second, longer phase ran from about one year to five years, with 1,464 participants continuing. The trial measured s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 96 reported results for Psoriatic Arthritis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research funding is currently directed toward Psoriatic Arthritis, and that level has remained broadly steady over time. This suggests the condition holds a consistent place on the research agenda, rather than experiencing sharp rises or falls in scientific interest. For patients, a steady funding base generally means ongoing scientific at...
See the full Psoriatic Arthritis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.